UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 172

Sortiert nach

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth

PloS one, 2021-03, Vol.16 (3), p.e0246244

2021

Volltextzugriff (PDF)

PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma

International journal of molecular sciences, 2023-12, Vol.25 (1), p.427

2023

Volltextzugriff (PDF)

PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells

PloS one, 2019-04, Vol.14 (4), p.e0214469-e0214469

2019

Volltextzugriff (PDF)

Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts

Scientific reports, 2019-09, Vol.9 (1), p.13259-12, Article 13259

2019

Volltextzugriff (PDF)

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Scientific reports, 2021-03, Vol.11 (1), p.5984-14, Article 5984

2021

Volltextzugriff (PDF)

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

Translational oncology, 2024-09, Vol.47, p.102045, Article 102045

2024

Volltextzugriff (PDF)

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Scientific reports, 2018-05, Vol.8 (1), p.6913-10, Article 6913

2018

Volltextzugriff (PDF)

Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma

Cancers, 2022-04, Vol.14 (8), p.1952

2022

Volltextzugriff (PDF)

FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma

Clinical & experimental metastasis, 2013-06, Vol.30 (5), p.555-568

2013

Volltextzugriff (PDF)

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

Cancers, 2022-02, Vol.14 (3), p.762

2022

Volltextzugriff (PDF)

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma

Translational oncology, 2019-02, Vol.12 (2), p.200-208

2019

Volltextzugriff (PDF)

Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines

Cancers, 2021-06, Vol.13 (13), p.3201

2021

Volltextzugriff (PDF)

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

Translational oncology, 2021-07, Vol.14 (7), p.101099, Article 101099

2021

Volltextzugriff (PDF)

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts

Translational oncology, 2021-01, Vol.14 (1), p.100893, Article 100893

2021

Volltextzugriff (PDF)

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

Translational oncology, 2019-01, Vol.12 (1), p.84-95

2019

Volltextzugriff (PDF)

Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival

The Journal of surgical research, 2015-06, Vol.196 (2), p.339-349

2015

Volltextzugriff (PDF)

Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma

PloS one, 2013-10, Vol.8 (10), p.e77753-e77753

2013

Volltextzugriff (PDF)

Using 3D-bioprinted models to study pediatric neural crest-derived tumors

International journal of bioprinting, 2023-01, Vol.9 (4), p.723-723

2023

Volltextzugriff (PDF)

Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors

PloS one, 2014-01, Vol.9 (1), p.e86843-e86843

2014

Volltextzugriff (PDF)

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

Translational oncology, 2019-10, Vol.12 (10), p.1364-1374

2019

Volltextzugriff (PDF)

Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells

Translational oncology, 2016-08, Vol.9 (4), p.263-273

2016

Volltextzugriff (PDF)

ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis

Cancer biology & therapy, 2007-03, Vol.6 (3), p.454-462

2007

Volltextzugriff (PDF)

PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin

Journal of pediatric surgery, 2024-07, Vol.59 (7), p.1334-1341

2024

Volltextzugriff (PDF)

Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma

Translational oncology, 2016-10, Vol.9 (5), p.419-430

2016

Volltextzugriff (PDF)

Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model

Cancer research (Chicago, Ill.), 2005-10, Vol.65 (20), p.9338-9346

2005

Volltextzugriff (PDF)

1 – 25 von 172

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(148)
Mit Volltextzugriff
(149)

Publikationsform

Sprache

Englisch
(172)
Japanisch
(14)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth

PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma

PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells

Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma

Preclinical evidence for employing MEK inhibition in NRAS mutated pediatric gastroenteropancreatic neuroendocrine-like tumors

FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts

Pre-Clinical Study Evaluating Novel Protein Phosphatase 2A Activators as Therapeutics for Neuroblastoma

FAK inhibition decreases cell invasion, migration and metastasis in MYCN amplified neuroblastoma

Targeting High-Risk Neuroblastoma Patient-Derived Xenografts with Oncolytic Virotherapy

Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma

Serine-Threonine Kinase Receptor-Associated Protein (STRAP) Knockout Decreases the Malignant Phenotype in Neuroblastoma Cell Lines

Downregulation of PDGFRß Signaling Overcomes Crizotinib Resistance in a TYRO3 and ALK Mutated Neuroendocrine-Like Tumor

9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts

Investigation of PP2A and Its Endogenous Inhibitors in Neuroblastoma Cell Survival and Tumor Growth

Focal adhesion kinase and p53 synergistically decrease neuroblastoma cell survival

Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of neuroblastoma

Using 3D-bioprinted models to study pediatric neural crest-derived tumors

Preclinical evaluation of engineered oncolytic herpes simplex virus for the treatment of pediatric solid tumors

UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts

Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells

ABT-510, a modified type 1 repeat peptide of thrombospondin, inhibits malignant glioma growth in vivo by inhibiting angiogenesis

PIM Kinase Inhibition Sensitizes Neuroblastoma to Doxorubicin

Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma

Low-density lipoprotein receptor-related protein contributes to the antiangiogenic activity of thrombospondin-2 in a murine glioma model

Suchergebnisse filtern